Market Access Insights
Access the relevant market access data and insights you need on health plans, policy restrictions, PBMs, providers, and more
Report
December 30, 2010
Formulary Advantages in Oral Oncology Drugs: Health plans respond to generic entry, base formulary decisions on survival data
Private and Medicare plans will continue their receptiveness to oral oncology therapies over the next five years, but anticipated increases in coinsurance rates and copays will shift more of the cost…
Report
December 15, 2010
Formulary Advantages in Therapies for Type II Diabetes: Crowding among anti-diabetic agents necessitates brand differentiation
Type 2 diabetes is a leading cause of cardiovascular disease, blindness, renal failure and neurologic dysfunction in the United States. Current epidemiologic studies estimate that nearly 24 million Am…
Report
December 1, 2010
Formulary Advantages in Analgesics for Chronic Pain: How will emerging reformulations and fixed-dose combinations fare among U.S. health plans?
Chronic pain syndromes of neuropathic, nociceptive and mixed origins cause substantial human suffering and disability. Despite the number of pain therapies marketed in the U.S., there remains an unfil…
